Avid Bioservices Inc (CDMO)

[entdoc]

jakedogman1, greatly appreciate the articles, which were well-written, and bring us all up to date on the Opdiva/Keytruda competition. Like PPHM, we remain clueless regarding trials which we, the stockholders pay for. This is only one tragedy identified in a ruthless "war on cancer" waged for profit since the days of Richard Nixon (and earlier). What do the pathology slides show in Bavi patients? How much of the MAB IS, in fact, seen in tumor vasculature, and tumor, and other places in this test? These kinds of questions, and their answers, are what I am looking for. Now I wonder if the Keytruda results were falsely high in light of the Opdiva subgroup analysis. I am sure BMY is going to be stratifying responders and non-responders on the percentage of PD-L1, yada. I an be double miffed because I own BMY also! Read my lips: Immune-Oncology treatment of advanced lung cancer is a pipe dream, and might help a precious few, which is interesting. The spin-off information gleaned with this (and the Bavi trial) will keep a lot of immunologist busy for a few years.